Tolvaptan Slows Loss of Renal Function in Later-Stage ADPKD
Reduction in decline in eGFR for patients with later-stage autosomal dominant polycystic kidney disease
Kidney Disease
Lixivaptan Gets Orphan Drug Status for Autosomal Dominant PKD
Lixivaptan is a potent, selective vasopressin V2 receptor antagonist which has been found to delay the progression of an autosomal dominant form of polycystic kidney disease.
Sleep Duration, Quality Tied to Chronic Kidney Disease Progression
Shorter sleep duration, greater sleep fragmentation linked to greater decline in eGFR
Intensive Blood Pressure Control Linked to Increased CKD Risk
However, cardiovascular events, all-cause mortality risk decrease with intensive blood pressure lowering
Acute Kidney Injury Seen in Marathon Runners
Injury and repair biomarker levels suggest structural damage to renal tubules
Orphan Drug Status Granted for C3 Glomerulopathy Treatment
Patients with C3G experience progressive deterioration in renal function, ultimately leading to renal failure requiring dialysis and kidney transplant, if left untreated.
